Valuation: Interpace Biosciences, Inc.

Market Cap 41.27M 36.18M 33.44M 30.76M 58.03M 3.98B 58.96M 400M 157M 1.95B 155M 152M 6.71B P/E 2024
6.84x
P/E 2025 1.39x
Enterprise Value 39.95M 35.02M 32.37M 29.77M 56.17M 3.85B 57.07M 387M 152M 1.89B 150M 147M 6.49B EV / Sales 2024
0.35x
EV / Sales 2025 0.11x
Free-Float
14.74%
Yield 2024 *
-
Yield 2025 -
1 day-2.30%
1 week-0.67%
Current month-8.59%
1 month-10.62%
3 months-27.17%
6 months-16.76%
Current year+21.12%
1 week 1.42
Extreme 1.42
1.62
1 month 1.42
Extreme 1.42
1.8
Current year 1.03
Extreme 1.03
2.4
1 year 0.77
Extreme 0.77
2.4
3 years 0.44
Extreme 0.4433
3.54
5 years 0.44
Extreme 0.4433
10.5
10 years 0.44
Extreme 0.4433
198
Manager TitleAgeSince
Chief Executive Officer 64 2020-11-30
Director of Finance/CFO 34 2023-04-20
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 79 2016-06-20
Director/Board Member 73 2015-12-31
Director/Board Member 64 2020-01-21
Date Insider Type Main position Quantity % Market Cap.
1/20/26
1315 Capital LLC
ConversionCompany 9,405,941 212.3938%
1/20/26
Ampersand Management LLC
ConversionCompany 13,861,386 313.0013%
2/1/24 Free

Chief Financial Officer

10,000 0.2314%
Change 5-day change 1-year change 3-year change Capi.($)
-2.30%-0.67%+73.24%-36.60% 42.24M
-3.23%-3.76%+89.08%+453.14% 38.87B
-0.66%+1.73%+15.49%+28.71% 23.24B
-1.71%-0.47%-21.94%-39.70% 7.55B
-2.43%-4.15%+5.55%+79.63% 4.89B
+0.35%-1.84%+12.76%+44.22% 2.93B
-2.53%+0.92%+128.21%-17.26% 1.9B
-4.46%-5.01%-22.11%+698.03% 1.88B
+1.21%+3.37%-9.74%-62.11% 1.8B
+7.53%+2.54%+31.12%+9.23% 1.76B
Average -0.82%-0.84%+30.16%+115.73% 8.49B
Weighted average by Cap. -1.91%-1.32%+46.71%+231.95%

Financials

2024 2025
Net sales 46.93M 41.13M 38.02M 34.97M 65.98M 4.53B 67.03M 455M 178M 2.21B 176M 172M 7.63B 38.73M 33.95M 31.38M 28.86M 54.45M 3.73B 55.32M 375M 147M 1.83B 145M 142M 6.3B
Net income 6.7M 5.87M 5.43M 4.99M 9.42M 646M 9.57M 64.93M 25.45M 316M 25.17M 24.62M 1.09B 24.58M 21.54M 19.91M 18.31M 34.55M 2.37B 35.11M 238M 93.33M 1.16B 92.28M 90.27M 3.99B
Net Debt 4.4M 3.85M 3.56M 3.27M 6.18M 424M 6.28M 42.58M 16.69M 207M 16.5M 16.14M 714M -1.32M -1.16M -1.07M -985K -1.86M -127M -1.89M -12.81M -5.02M -62.38M -4.96M -4.86M -215M
Logo Interpace Biosciences, Inc.
Interpace Biosciences, Inc. provides esoteric molecular diagnostic testing and pathology services to aid physicians in the evaluation of cancer risk. The Company’s clinical services business commercializes clinically useful molecular diagnostic tests and molecular pathology services. The Company develops and commercializes genomic tests and related first-line assays that can personalize medicine to help improve patient diagnosis and management. It has five commercialized molecular diagnostic tests: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, and RespriDX. PancraGEN is a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians’ better risk-stratify pancreaticobiliary cancers using the Company’s proprietary PathFinderTG platform. PanDNA is an alternate reporting option of the PathFinderTG platform, which provides physicians the molecular only information. ThyGeNEXT is an oncogenic mutation panel that helps rule-in and rule-out malignancy in thyroid nodules.
Employees
102
Date Price Change Volume
26-07-20 $1.490 -2.30% 4,423
26-07-17 $1.525 -1.61% 2,060
26-07-16 $1.550 -4.32% 2,594
26-07-15 $1.620 0.00% 800
26-07-14 $1.620 +8.00% 1,035

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IDXG Stock